TriArm Therapeutics Completed $20 Million In Series A Financing

TriArm Therapeutics just completed 20 million dollars in Series A financing. This round of financing was led by Panacea Venture, and followed by Virtus Inspire Ventures, Efung Investment and few other institutions. The funds will be used to improve research speed for new drugs, build new production pipelines and improve the company's clinical research capabilities.

TriArm Therapeutics was founded in 2018, the company focuses on clinical research in novel cellular immunotherapeutic products and works to provide cancer patients with next-generation cell therapy products. At this moment, TriArm has a cell therapy research and development base in Shanghai, and is now working with many research institutions around the world.

"TriArm has the closest non-viral gene transfer technology for clinical applications, reducing the time-consuming CAR-T cell preparation process to 2-3 days, greatly reducing the cost and time of cell therapy product manufacturing. In the future, the company will continue to bring a series of innovative products for tumor immunotherapy through cooperative research and development," Dr. Jinhua Lu, co-founder and chief scientific officer of TriArm said.

Panacea Venture is a new investment firm in China.

Virtus Inspire Ventures is a boutique venture capital fund that offers seed, venture, and growth-stage funding in Asia.

Efung Investment is an institution that invests in professional biomedical industries in China.